{
    "clinical_study": {
        "@rank": "3197", 
        "arm_group": [
            {
                "arm_group_label": "Calcium electroporation", 
                "arm_group_type": "Experimental", 
                "description": "The metastases will be treated with intratumoral injection of calcium chlorid followed by electrotransfer.\nIt is a once-only treatment. Calcium chlorid concentration: 9mg/ml. Total dose: 0,5ml/cm3 tumor volume."
            }, 
            {
                "arm_group_label": "Electrochemotherapy with bleomycin", 
                "arm_group_type": "Active Comparator", 
                "description": "The metastases will be treated with intratumoral injection of bleomycin followed by electrotransfer.\nIt is a once only treatment. bleomycin concentration: 1000 IU/ml. Total dose: o,5 ml/cm3 tumor volume."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of calcium electroporation on cutaneous\n      metastases, and compare calcium electroporation with standard treatment:\n      electrochemotherapy."
        }, 
        "brief_title": "Calcium Electroporation for the Treatment of Cutaneous Metastases", 
        "condition": "Cutaneous Metastases", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Skin Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Double-blinded phase II clinical study. We will compare the effect of calcium\n      electroporation for the treatment of cutaneous metastases with standard treatment:\n      electrochemotherapy with intratumoral injection of bleomycin. Separate randomisation will be\n      performed and the lesions will be treated with either intratumoral injection of calcium or\n      bleomycin. It is a once only treatment and the patients will be followed up for 6 months.\n\n      It is a non-inferiority study and we accept a difference in response on 15%."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 18 years.\n\n          -  Histological confirmed cutaneous metastases of any histology.\n\n          -  At least 1. cutaneous metastases between 0,5 to 3cm, available to electroporation.\n\n          -  Patient should have been offered standard treatment.\n\n          -  At least 2 weeks since chemotherapy or radiotherapy.\n\n          -  Performance status >2 (ECOG).\n\n          -  Life expectancy >3 months.\n\n          -  platelet count > 50 mia/l.\n\n          -  International Normalized Ratio (INR) <1,2.\n\n          -  Men and women of reproductive age must use effective contraception during the study.\n\n          -  Patient should be able to understand participants information.\n\n          -  Signed, informed consent.\n\n        Exclusion Criteria:\n\n          -  Previously treatment with bleomycin > 200.000 Units/m2.\n\n          -  Allergy to bleomycin.\n\n          -  Clinically significant coagulopathy.\n\n          -  Pregnancy or lactation.\n\n          -  Participation in other clinical trial involving experimental drugs or participation\n             in a clinical trial within 4 weeks before study treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941901", 
            "org_study_id": "AA1232"
        }, 
        "intervention": [
            {
                "arm_group_label": "Calcium electroporation", 
                "description": "Intratumoral injection, once only treatment.", 
                "intervention_name": "Calcium electroporation", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Calcium chloride.", 
                    "ATC code: A02AC", 
                    "EV substance code SUB12664MIG"
                ]
            }, 
            {
                "arm_group_label": "Electrochemotherapy with bleomycin", 
                "description": "Intratumoral injection, once only treatment", 
                "intervention_name": "Electrochemotherapy with bleomycin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ATC code L01DC01", 
                    "EV substance code SUB00844MIG"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bleomycin", 
                "Calcium, Dietary"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Cutaneous metastases", 
        "lastchanged_date": "September 10, 2013", 
        "location": {
            "contact": {
                "email": "julie.gehl@regionh.dk", 
                "last_name": "Julie Gehl", 
                "phone": "004538683868"
            }, 
            "facility": {
                "address": {
                    "city": "Herlev", 
                    "country": "Denmark", 
                    "zip": "2730"
                }, 
                "name": "Department of Oncology, Copenhagen University Hospital, Herlev"
            }, 
            "investigator": {
                "last_name": "Julie Gehl", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "description": "It is a non-inferiority study, and we accept a difference in response on 15%.", 
            "measure": "Compare tumor response of calcium electroporation with tumor response of electroporation. Response is evaluated  by RECIST criteria.", 
            "safety_issue": "No", 
            "time_frame": "After 6 months"
        }, 
        "overall_contact": {
            "email": "julie.gehl@regionh.dk", 
            "last_name": "Julie Gehl", 
            "phone": "004538683868"
        }, 
        "overall_official": {
            "affiliation": "Department of Oncology, Copenhagen University hospital, Herlev", 
            "last_name": "Julie Gehl", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Response evaluated by \"Response Evaluation Criteria in Solid Tumors\" (RECIST) guidelines version 1.1.", 
            "measure": "Tumor response", 
            "safety_issue": "No", 
            "time_frame": "After 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941901"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Herlev Hospital", 
            "investigator_full_name": "Julie Gehl", 
            "investigator_title": "Medical Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Describe adverse events using Common Terminology for Adverse Events, version 4.0", 
            "measure": "Adverse events to calcium electroporation", 
            "safety_issue": "No", 
            "time_frame": "After 6 months"
        }, 
        "source": "Herlev Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Herlev Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}